Thursday’s FDA decision on bictegravir plus lenacapavir will test how much of Gilead’s future depends on a...
Three power-infrastructure bets in one month suggest a supply-chain strategy that many investors are treating as philanthropy.
Healthcare has outrun SOXX since June. The flows have barely started.
Three separate catalysts converged this week to produce Bitcoin's strongest weekly gain since March 2023. Only one...
Tariff refunds made the quarter. The Q3 guide reveals the margin question.
T-bills still pay. Long Treasuries are bleeding. The $7.93 trillion parked in money markets is sitting on...
A rogue agent, a paused frontier run, and a monitoring overhead that reshapes the unit economics of...
The Jevons Paradox is alive in the GPU market. Falling token prices expand the addressable universe of...
A 20% post-earnings drop on record revenue is not a verdict on the business. It is a...
HBM is sold out. DRAM is tightening. These four companies are not equally priced for what comes...